Product Pipeline

We are developing novel checkpoint inhibitors and immuno-oncology therapies that we believe may overcome some of the limitations of current immuno-oncology therapies. Three of these programs are aimed at disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment or by blocking its production by tumors. A fourth program is aimed at developing product candidates that regulate T-cell activation and differentiation.

Adenosine A2A Receptor Antagonist CPI-444
Adenosine Production Inhibitor Anti-CD73
Adenosine A2B Receptor Antagonist
ITK Inhibitor